Compugen (Israel) Performance
| CGEN Stock | ILA 516.60 5.00 0.96% |
The firm shows a Beta (market volatility) of 0.14, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Compugen's returns are expected to increase less than the market. However, during the bear market, the loss of holding Compugen is expected to be smaller as well. At this point, Compugen has a negative expected return of -0.7%. Please make sure to confirm Compugen's jensen alpha, treynor ratio, value at risk, as well as the relationship between the total risk alpha and maximum drawdown , to decide if Compugen performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Compugen has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 7.8 M | |
| Total Cashflows From Investing Activities | 6.6 M |
Compugen |
Compugen Relative Risk vs. Return Landscape
If you would invest 72,900 in Compugen on August 29, 2024 and sell it today you would lose (21,240) from holding Compugen or give up 29.14% of portfolio value over 90 days. Compugen is generating negative expected returns and assumes 3.0054% volatility on return distribution over the 90 days horizon. Simply put, 26% of stocks are less volatile than Compugen, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Compugen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Compugen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Compugen, and traders can use it to determine the average amount a Compugen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2333
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CGEN |
Estimated Market Risk
| 3.01 actual daily | 26 74% of assets are more volatile |
Expected Return
| -0.7 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.23 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Compugen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Compugen by adding Compugen to a well-diversified portfolio.
Compugen Fundamentals Growth
Compugen Stock prices reflect investors' perceptions of the future prospects and financial health of Compugen, and Compugen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Compugen Stock performance.
| Return On Equity | -0.44 | |||
| Return On Asset | -0.23 | |||
| Current Valuation | 12.53 M | |||
| Shares Outstanding | 86.62 M | |||
| Price To Book | 1.13 X | |||
| Price To Sales | 46.89 X | |||
| Revenue | 6 M | |||
| EBITDA | (35.07 M) | |||
| Cash And Equivalents | 110.41 M | |||
| Cash Per Share | 1.32 X | |||
| Total Debt | 2.85 M | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 0.92 X | |||
| Cash Flow From Operations | (22.75 M) | |||
| Earnings Per Share | (0.40) X | |||
| Total Asset | 132.16 M | |||
| Current Asset | 91 M | |||
| Current Liabilities | 6.85 M | |||
About Compugen Performance
By analyzing Compugen's fundamental ratios, stakeholders can gain valuable insights into Compugen's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Compugen has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Compugen has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. COMPUGEN operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 68 people.Things to note about Compugen performance evaluation
Checking the ongoing alerts about Compugen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Compugen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Compugen generated a negative expected return over the last 90 days | |
| Compugen has high historical volatility and very poor performance | |
| The company reported the revenue of 6 M. Net Loss for the year was (34.2 M) with profit before overhead, payroll, taxes, and interest of 5.32 M. | |
| Compugen has accumulated about 110.41 M in cash with (22.75 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.32. |
- Analyzing Compugen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Compugen's stock is overvalued or undervalued compared to its peers.
- Examining Compugen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Compugen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Compugen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Compugen's stock. These opinions can provide insight into Compugen's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Compugen Stock analysis
When running Compugen's price analysis, check to measure Compugen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compugen is operating at the current time. Most of Compugen's value examination focuses on studying past and present price action to predict the probability of Compugen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compugen's price. Additionally, you may evaluate how the addition of Compugen to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |